16 assets in ALK-Positive Anaplastic Large Cell Lymphoma

Therapeutic assets addressing ALK-Positive Anaplastic Large Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Etoposide ALK-Positive Anaplastic Large Cell Lymphoma	Mingzhi Zhang	P4	BB (70)
Adriamycin ALK-Positive Anaplastic Large Cell Lymphoma	Huiqiang Huang	P2	BB (66)
Cyclophosphamide ALK-Positive Anaplastic Large Cell Lymphoma	Huiqiang Huang	P2	BB (65)
Brentuximab Vedotin ALK-Positive Anaplastic Large Cell Lymphoma	New York Medical College	P2	BB (64)
Prednisone ALK-Positive Anaplastic Large Cell Lymphoma	Huiqiang Huang	P2	BB (64)
Alectinib ALK-Positive Anaplastic Large Cell Lymphoma	Nuvalent Inc.	P3	B (60)
Neladalkib ALK-Positive Anaplastic Large Cell Lymphoma	Nuvalent Inc.	P3	B (60)
Pralatrexate ALK-Positive Anaplastic Large Cell Lymphoma	Corvus Pharmaceuticals, Inc.	P3	B (60)
Soquelitinib ALK-Positive Anaplastic Large Cell Lymphoma	Corvus Pharmaceuticals, Inc.	P3	B (60)
Belinostat ALK-Positive Anaplastic Large Cell Lymphoma	Corvus Pharmaceuticals, Inc.	P3	B (58)
Brigatinib ALK-Positive Anaplastic Large Cell Lymphoma	Princess Maxima Center for Pediatric Oncology	P2	B (58)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE ALK-Positive Anaplastic Large Cell Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab ALK-Positive Anaplastic Large Cell Lymphoma	New York Medical College	P2	CCC (53)
Vinblastine ALK-Positive Anaplastic Large Cell Lymphoma	New York Medical College	P2	CCC (53)
c7r.cd30.car-ebvst cells ALK-Positive Anaplastic Large Cell Lymphoma	Baylor College of Medicine	P1	CC (43)
Gilteritinib ALK-Positive Anaplastic Large Cell Lymphoma	Astellas Pharma Global Development, Inc.	P1	CC (43)